Biologics

Researchers identified the human skeletal stem cell and derived it from induced pluripotent stem cells, according to findings published in Cell Stem Cell.

Pablo Pazmino, MD, medical director of Spine Cal in Santa Monica, Calif., discusses the key trends in spinal and neurospine technology and how he evaluates new technology for his practice.

R. Brandon Trale, DO, performed a partial hip replacement case as part of a Pluristem Therapeutics stem cell trial at Indiana (Pa.) Regional Medical Center, according to The Indiana Gazette.

NuVasive launched three new biologics offerings for the spine industry.

Cost management solutions company Tempus Innovations partnered with Regenexx to provide reduced-cost, non-surgical treatments to injured workers.

Here are 10 key players in the global orthopedic biomaterials market, according to a Market iFrame report.

MIACH Orthopaedics, a bioengineered surgical implant company, completed $22.5 million in financing.

UC San Diego researchers derived spinal cord neural stem cells from human pluripotent stem cells transplanted  into a rat model with spinal cord injury, according to a study in Nature Methods.

University of Toledo (Ohio) researchers developed a smart injectable calcium phosphate bone cement for orthopedic and spinal fusion applications. The smart CaP compositions were biocompatible, according to a study in Materials.

Best in Class Care entered an agreement with Regenexx to reduce high-cost musculoskeletal surgeries and accelerate employers' ability to directly contract with its network of providers.